Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: Evidence from a therapeutic drug monitoring service
Autore:
Weigmann, H; Gerek, S; Zeisig, A; Muller, M; Hartter, S; Hiemke, C;
Indirizzi:
Univ Mainz, Dept Psychiat, D-55131 Mainz, Germany Univ Mainz Mainz Germany D-55131 , Dept Psychiat, D-55131 Mainz, Germany
Titolo Testata:
THERAPEUTIC DRUG MONITORING
fascicolo: 4, volume: 23, anno: 2001,
pagine: 410 - 413
SICI:
0163-4356(200108)23:4<410:FBNSIT>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
SEROTONIN REUPTAKE INHIBITORS; ANTIPSYCHOTIC AGENT OLANZAPINE; SERUM CONCENTRATIONS; IN-VITRO; CLOZAPINE; SCHIZOPHRENIA; CARBAMAZEPINE; PSYCHOSES; EFFICACY;
Keywords:
olanzapine; fluvoxamine; sertraline; therapeutic drug monitoring; pharmacokinetic interactions;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
25
Recensione:
Indirizzi per estratti:
Indirizzo: Hiemke, C Univ Mainz, Dept Psychiat, Untere Zahlbacher Str 8, D-55131 Mainz, Germany Univ Mainz Untere Zahlbacher Str 8 Mainz Germany D-55131 ermany
Citazione:
H. Weigmann et al., "Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: Evidence from a therapeutic drug monitoring service", THER DRUG M, 23(4), 2001, pp. 410-413

Abstract

Therapeutic drug monitoring data of the new atypical neuroleptic drug olanzapine were used to study interactions with the selective serotonin reuptake inhibitors fluvoxamine and sertraline. The distribution of the ratio of concentration/daily dose (C/D, ng/mL per mg/d) of olanzapine was compared inthree groups: patients treated with olanzapine (n = 134), patients treatedwith olanzapine plus fluvoxamine (n = 10) concomitantly, and patients treated with olanzapine plus sertraline (n = 21) concomitantly. No significant difference was seen between the olanzapine and the olanzapine plus sertraline groups. Patients receiving fluvoxamine in addition to olanzapine had C/Dratios that were in the mean 2.3-fold higher than patients receiving olanzapine, without additional fluvoxamine. This indicated that fluvoxamine inhibits the metabolism of olanzapine, probably because of inhibition of cytochrome P450 (CYP) 1A2, whereas sertraline is unlikely to interfere with the metabolism of olanzapine. Combination therapy of olanzapine and fluvoxamine should be used cautiously, and therapeutic drug monitoring should be instituted to avoid olanzapine-induced adverse effects or intoxications.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/01/20 alle ore 13:55:28